| Date Filed | Type | Description |
| 10/02/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/24/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 07/17/2023 |
SC 13G
| BML Investment Partners, L.P. reports a 5.1% stake in Quince Therapeutics, Inc. |
| 04/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 04/27/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/29/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/17/2023 |
SC 13G
| BML Investment Partners, L.P. reports a 5.2% stake in Embark Technology, Inc. |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 13.7% stake in Astrotech Corporation |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 0% stake in Terns Pharmaceuticals, Inc. |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 0% stake in Terns Pharmaceuticals, Inc. |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 7.8% stake in Pardes Biosciences Inc |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 5.7% stake in Graybug Vision, INC. |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 19.9% stake in Satsuma Pharmaceuticals, Inc. |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 7.3% stake in Adverum Biotechnologies, Inc. |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 7.1% stake in Eliem Therapeutics, Inc. |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 5.5% stake in Tillys, Inc |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/08/2023 |
SC 13G/A
| BML Investment Partners, L.P. reports a 3.2% stake in Retractable Technologies, Inc. |
| 02/02/2023 |
SC 13G
| BML Investment Partners, L.P. reports a 5.6% stake in Surrozen, Inc./DE |
| 01/26/2023 |
SC 13G
| BML Investment Partners, L.P. reports a 7.7% stake in Cyteir Therapeutics, Inc. |
| 01/09/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/30/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/08/2022 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 12/01/2022 |
SC 13G
| BML Investment Partners, L.P. reports a 5.7% stake in Graybug Vision, INC. |
| 11/16/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 10/17/2022 |
SC 13G/A
| BML Investment Partners, L.P. reports a 5.4% stake in Tillys, Inc |
| 08/25/2022 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 08/16/2022 |
SC 13D/A
| BML Investment Partners, L.P. reports a 7.2% stake in Forte Biosciences, Inc. |
| 07/07/2022 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 06/07/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
|